C. Stürzebecher

Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity.

H. Vorbrüggen, W. Skuballa, E. Schillinger, 1986, Journal of medicinal chemistry.

Frequency of blood CX3CR1‐positive natural killer cells correlates with disease activity in multiple sclerosis patients

J. Wuerfel, F. Zipp, J. Bellmann-Strobl, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes

L. Staudt, A. Rosenwald, Roland Martin, 2001, Annals of neurology.

Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.

R. Horowski, J. Kapp, C. Stürzebecher, 2001, Functional neurology.

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis

Roland Martin, H. McFarland, N. Richert, 2009, Multiple sclerosis.

Immunotherapy of multiple sclerosis: Where are we? Where should we go?

Roland Martin, H. McFarland, C. Stürzebecher, 2001, Nature Immunology.

Design of Individual Donor Feedback Processes in Biobank Research

N. Luttenberger, R. Kollek, J. Reischl, 2006, GI Jahrestagung.